Scientists hunt for clues to make cancer immunotherapy work for more patients
NCT ID NCT04603248
Summary
This study aims to find better ways to predict which patients with advanced head and neck cancer will benefit from the immunotherapy drug nivolumab. Researchers will analyze blood and tumor samples from 50 patients to look for biological markers linked to treatment success. The goal is to help doctors select the right patients for this therapy sooner and more accurately.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.